DTC-and-Me: Patient, Provider, Proteins and Regulators
SomaLogic Inc., 2945 Wilderness Pl., Boulder, CO 80301, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2014, 4(1), 79-87; https://doi.org/10.3390/jpm4010079
Received: 13 December 2013
/
Revised: 6 March 2014
/
Accepted: 7 March 2014
/
Published: 18 March 2014
(This article belongs to the Special Issue Bringing Personalized Medicine into Clinical Practice 2013)
The yet-unrealized potential for more “personalized” Direct-to-Consumer (DTC) tests to fundamentally alter the practice and economics of healthcare is undeniable. However, there are also many challenges to be met, including the herculean task of ensuring that the information provided by such tests is scientifically sound and, ideally, medically actionable. We consider recent events in DTC testing and suggest a “thought experiment” of an approach that could ultimately meet the needs of patients, providers and regulatory authorities.
View Full-Text
Keywords:
proteomics; personalized medicine; SOMAmer; aptamer; SOMAscan; diagnostics; direct-to-consumer
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License.
MDPI and ACS Style
Steele, F.R.; Gold, L. DTC-and-Me: Patient, Provider, Proteins and Regulators. J. Pers. Med. 2014, 4, 79-87. https://doi.org/10.3390/jpm4010079
AMA Style
Steele FR, Gold L. DTC-and-Me: Patient, Provider, Proteins and Regulators. Journal of Personalized Medicine. 2014; 4(1):79-87. https://doi.org/10.3390/jpm4010079
Chicago/Turabian StyleSteele, Fintan R., and Larry Gold. 2014. "DTC-and-Me: Patient, Provider, Proteins and Regulators" Journal of Personalized Medicine 4, no. 1: 79-87. https://doi.org/10.3390/jpm4010079
Find Other Styles
